PROTRIEVE Trademark

Trademark Overview


On Friday, September 28, 2018, a trademark application was filed for PROTRIEVE with the United States Patent and Trademark Office. The USPTO has given the PROTRIEVE trademark a serial number of 88136782. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 9, 2022. This trademark is owned by Allergan Sales, LLC. The PROTRIEVE trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations, intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medic...
protrieve

General Information


Serial Number88136782
Word MarkPROTRIEVE
Filing DateFriday, September 28, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 9, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 5, 2019

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations, intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antimicrobial preparations for inhibiting microbiological decomposition in pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, Central Nervous System disease and disorders, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent for medical purposes; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, October 6, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Trademark Events


Event DateEvent Description
Monday, May 9, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 9, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, September 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 9, 2021SOU EXTENSION 5 GRANTED
Thursday, September 2, 2021SOU EXTENSION 5 FILED
Thursday, September 9, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 2, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 26, 2021SOU EXTENSION 4 GRANTED
Friday, March 26, 2021SOU EXTENSION 4 FILED
Friday, March 26, 2021SOU TEAS EXTENSION RECEIVED
Saturday, September 19, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 17, 2020SOU EXTENSION 3 GRANTED
Thursday, September 17, 2020SOU EXTENSION 3 FILED
Thursday, September 17, 2020SOU TEAS EXTENSION RECEIVED
Thursday, March 26, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 24, 2020SOU EXTENSION 2 GRANTED
Tuesday, March 24, 2020SOU EXTENSION 2 FILED
Tuesday, March 24, 2020SOU TEAS EXTENSION RECEIVED
Thursday, September 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019SOU EXTENSION 1 GRANTED
Tuesday, September 24, 2019SOU EXTENSION 1 FILED
Tuesday, September 24, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, April 2, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 5, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 5, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 16, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 28, 2018ASSIGNED TO LIE
Friday, December 7, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 14, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 14, 2018NON-FINAL ACTION E-MAILED
Wednesday, November 14, 2018NON-FINAL ACTION WRITTEN
Tuesday, November 13, 2018ASSIGNED TO EXAMINER
Saturday, October 6, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 2, 2018NEW APPLICATION ENTERED